OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Stilwill on Adjuvant Advances in Melanoma

July 5th 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses adjuvant advances in the treatment of patients with melanoma.

Dr. Kwa on the TAILORx Trial in Breast Cancer

July 5th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

July 4th 2018

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).

Dr. Barr on Systemic Therapies for Patients With Neuroendocrine Tumors

July 4th 2018

Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses systemic therapies for patients with neuroendocrine tumors (NETs).

Dr. Levy on the Application of Liquid Biopsies in NSCLC

July 4th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the application of liquid biopsies in non–small-cell lung cancer (NSCLC).

Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer

July 4th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Dr. Maughan on Enzalutamide Plus Radium-223 in mCRPC

July 4th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses enzalutamide (Xtandi) plus radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Choueiri Discusses Checkpoint Inhibitors in RCC

July 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Dr. El-Deiry on Liquid Vs Tissue Biopsies

July 3rd 2018

Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director, Translational Research Program, co-leader, Molecular Therapeutics Program, professor, Department Hematology/Oncology, Fox Chase Cancer Center, discusses the advantages of liquid biopsies over tissue biopsies.

Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell Lymphoma

July 3rd 2018

Jeffrey Humphrey, MD, president, Kyowa Hakko Kirin Pharma, Inc., discusses the benefits of mogamulizumab for the treatment of cutaneous T-cell lymphoma.

Dr. Yardley on the Role of Biosimilars in Breast Cancer

July 3rd 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the role of biosimilars in the treatment of patients with breast cancer.

Dr. Rini on the Tolerability of Atezolizumab Plus Bevacizumab in RCC

July 3rd 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the tolerability of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Brentjens Discusses the Future of CAR T-Cell Therapy

July 3rd 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor T-cell therapy.

Dr. Liu on ALK-Targeted Agents in NSCLC

July 3rd 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses ALK-targeted agents in the field of non–small cell lung cancer (NSCLC).

Dr. Langer on the IMpower150 Trial in NSCLC

July 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer

July 3rd 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).

Dr. Trotman Discusses Zanubrutinib in Waldenstrom's Macroglobulinemia

June 29th 2018

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of medicine, Concord Clinical School, director of Clinical Research Unit, Haematology Department, Concord Hospital, discusses zanubrutinib in patients with Waldenstrom's Macroglobulinemia.

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

June 29th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Dr. Villaruz Discusses PD-L1 Expression in Lung Cancer

June 29th 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC

June 29th 2018

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses the updated efficacy and safety data from the global phase III ALEX study of alectinib (Alecensa) versus crizotinib (Xalkori) in untreated advanced ALK-positive non–small cell lung cancer (NSCLC).